12 minute read
Dec. 1, 2023
Danuglipron: An Oral GLP-1R Agonist Competing with Peptide Injectables for Diabetes and Obesity
danuglipron
oral GLP-1-RA full agonist obesity Ph. IIb, 2.5-120 mg QD, T2D Ph. II, 40-200 mg from sensitized cell HTS of 2.8M cmpds + opt. Press release, June 26, 2023 Pfizer, Cambridge, MA
Loading...
